Lacosamide Epilepsy Medication
Links shared publicly online about this topic
Lacosamide Validated As Promising Therapy For Uncontrolled Partial-Onset Seizures
medicalnewstoday.com — “A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seiz” View full resource at medicalnewstoday.com
Most Recently Shared on February 26, 2010 at 4:07 pm By:
Lacosamide Validated As Promising Therapy For Uncontrolled Partial-Onset Seizures http://mnt.to/3ybp #epilepsy
Epilepsy
kidshealth.org — “Epilepsy causes electrical signals in the brain to misfire, which can lead to multiple seizures over a period of time. Anyone can get epilepsy at any age, but the majority of new diagnoses are in kids.” View full resource at kidshealth.org
Most Recently Shared on August 13, 2009 at 1:07 pm By:
Neurology Medical News about Epilepsy, Partial, Motor
mdlinx.com — “Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial” View full resource at mdlinx.com
Most Recently Shared on January 29, 2010 at 9:21 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Neuro: Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial: Epilepsia http://url4.eu/1GEdu
Neurology Medical News about Epilepsy, Partial, Motor
mdlinx.com — “New treatment option for partial-onset seizures: efficacy and safety of lacosamide” View full resource at mdlinx.com
Most Recently Shared on March 22, 2010 at 9:39 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
New treatment option for partial-onset seizures: efficacy and safety of lacosamide: Therapeutic ... http://bit.ly/9CzZ5b #neurology #mdlinx
Study confirms efficacy and tolerability of lacosamide for uncontrolled POS
news-medical.net — “A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.” View full resource at news-medical.net
Most Recently Shared on February 26, 2010 at 5:41 am By:
Study confirms efficacy and tolerability of lacosamide for uncontrolled POS: A recent multi-center study has confi... http://bit.ly/9sdJGi
New Data On Vimpat® (lacosamide) C-V To Be Presented At The 64th Annual Meeting Of The American Epilepsy Society
medicalnewstoday.com — “New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Conven” View full resource at medicalnewstoday.com
Most Recently Shared on December 1, 2010 at 5:05 pm By:
New Data On Vimpat® (lacosamide) C-V To Be Presented At The 64th Annual Meeting Of The American Epilepsy Society http://mnt.to/3NmQ
Internal Med Medical News about Epilepsy, Partial, Motor
mdlinx.com — “Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial” View full resource at mdlinx.com
Most Recently Shared on January 29, 2010 at 10:13 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Int Med: Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial: Epilepsia http://url4.eu/1GGFh
ScienceDirect - Epilepsy & Behavior : Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine
sciencedirect.com — “ScienceDirect - Epilepsy & Behavior : Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine” View full resource at sciencedirect.com
Most Recently Shared on May 22, 2011 at 3:53 am By:
Edgar Avalos, MD Neurology and Health Group
Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine http://dx.doi.org/10.1016/j.yebeh.2011.01.022
UCB Media Centre - Vimpat® (lacosamide) provided sustained efficacy and good tolerability for up to 8 years in patients with partial onset seizures
ucb.presscentre.com — “For the attention of accredited medical writers only• Long term data from four open label lacosamide extension trials reported at the 29th International Epilepsy Congress • New non-interventional study (VITOBA™) aims to investigate additive or synergistic effects of lacosamide with single antiepileptic drug (AED) treatment” View full resource at ucb.presscentre.com
Most Recently Shared on August 31, 2011 at 12:24 pm By:
Actually the UCB/Vimpat link is this: http://t.co/Sgp6Aff
New Data on Vimpat (lacosamide) C-V to be Presented at the 64th Annual Meeting of the American Epilepsy Society - Drugs.com MedNews
drugs.com — “Data on Keppra XR (levetiracetam) extended release tablets and Brivaracetam will also be presented New data on UCB s anti-epileptic drug (AED) Vimpat (lacosamid” View full resource at drugs.com
Most Recently Shared on November 30, 2010 at 4:15 pm By:
Drugs and Devices OW OW Health
New Data on Vimpat (lacosamide) C-V to be Presented at the 64th Annual Meeting of the American Epilepsy So... http://bit.ly/hr1oKI #drug
Noncompliance with Epilepsy Medication is Concerning
emaxhealth.com — “A study conducted by researchers at the Cincinnati Children--™s Hospital Medical Center has found that medication adherence among children with newly ...” View full resource at emaxhealth.com
Most Recently Shared on April 28, 2011 at 2:47 pm By:
Denise Reynolds RD Nutritionist and Dietitian
Noncompliance with Epilepsy Medication is Concerning http://bit.ly/k934ou
Medical Student Article | Epilepsy
mdlinx.com — “A population-based study of long-term outcomes of cryptogenic focal epilepsy in childhood: Cryptogenic epilepsy is probably not symptomatic epilepsy” View full resource at mdlinx.com
Most Recently Shared on February 17, 2011 at 8:52 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Dr Elaine C. Wirrell just commented on: A population-based study of long-term outcomes of cryptogeni... http://bit.ly/eephOJ #authorcmnt
Newly-Published Study Reinforces Role Of Antiepileptic Drug Vimpat(R) (lacosamide) (C-V) As An Add-on Treatment That Significantly Reduces Epilepsy
medicalnewstoday.com — “UCB announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a” View full resource at medicalnewstoday.com
Most Recently Shared on March 12, 2010 at 3:11 pm By:
Newly-Published Study Reinforces Role Of Antiepileptic Drug Vimpat(R) (lacosamide) (C-V) As An Add-on Treatment That S... http://mnt.to/3yQ3
Medical Student Article | Epilepsy
mdlinx.com — “Age at onset predicts good seizure outcome in sporadic non-lesional and mesial temporal sclerosis based temporal lobe epilepsy” View full resource at mdlinx.com
Most Recently Shared on November 23, 2010 at 1:47 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Dr Dr A Labate just commented on: Age at onset predicts good seizure outcome in sporadic non-lesiona... http://bit.ly/fLszx1 #authorcmnt
Study Reinforces Role Of AED Vimpat (Lacosamide) (C-V) As Add-On Treatment For POS
medicalnewstoday.com — “UCB has announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according” View full resource at medicalnewstoday.com
Most Recently Shared on March 12, 2010 at 4:11 pm By:
Study Reinforces Role Of AED Vimpat (Lacosamide) (C-V) As Add-On Treatment For POS http://mnt.to/3yQt #epilepsy
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MNT Epilepsy News
The latest epilepsy news published daily. Articles from research centers, universities and prestigious journals.
-
KidsHealth
KidsHealth is the most-trusted website for health and development information written for parents, kids and teens.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
